KYMR
NASDAQ HealthcareKymera Therapeutics, Inc. - Common Stock
Biotechnology
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
�� 市场数据
| 价格 | $87.71 |
|---|---|
| 成交量 | 563,495 |
| 市值 | 7.16B |
| 贝塔系数 | 2.290 |
| RSI（14日） | 71.5 超买 |
| 200日均线 | $65.18 |
| 50日均线 | $83.81 |
| 52周最高 | $103.00 |
| 52周最低 | $25.50 |
| Forward P/E | -21.88 |
| Price / Book | 4.52 |
🎯 投资策略评分
KYMR 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (95/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 💰 Dividend Daddy (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 KYMR in your text
粘贴任何文章、记录或帖子 — 工具将提取 KYMR 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.